Amgen Inc. Stock , AMGN

385.16 -2.51 -0.65%
03:59:59 PM EDT 7/31/2026 BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 07/31/2026 the closing price of the Amgen Inc. share was $387.67 on BTT. Compared to the opening price on Friday 07/31/2026 on BTT of $380.35, this is a gain of 1.89%. Amgen Inc.'s market capitalization is $168.89 B by 539.71 M shares outstanding.
Is Amgen stock a Buy, Sell or Hold? Amgen stock has received a consensus rating of hold. The average rating score is Baa1 and is based on 16 buy ratings, 35 hold ratings, and 4 sell ratings.
What was the 52-week low for Amgen stock? The low in the last 52 weeks of Amgen stock was 269.78. According to the current price, Amgen is 142.77% away from the 52-week low.
What was the 52-week high for Amgen stock? The high in the last 52 weeks of Amgen stock was 397.81. According to the current price, Amgen is 96.82% away from the 52-week high.
What are analysts forecasts for Amgen stock? The 55 analysts offering price forecasts for Amgen have a median target of 336.25, with a high estimate of 432.00 and a low estimate of 261.00. The median estimate represents a 114.54 difference from the last price of 385.16.

Amgen Stock Snapshot

361.95
Bid
40.00
Bid Size
402.15
Ask
40.00
Ask Size
7/31/2026
Date
3:59 PM
Time
70,519.00
Volume
387.67
Prev. Close
382.88
Open
207.87 B
Market Cap in USD
539.71 M
Number of Shares
539.71 M
Total Number of Shares
379.50
Day Low
386.71
Day High
385.16
269.78
52 Week Low
397.81
52 Week High
385.16
9.52
Dividend in USD
2.91
Dividend Yield
23.01
P/E Ratio
99.77
Free Float in %
14.23
EPS in USD
16.07
Book Value per Share in USD
18.37
Cash Flow per Share in USD

Historical Prices for Amgen

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Amgen Analyst Data

Total Analysts: 55
Buy Ratings: 16 Neutral Ratings: 35 Sell Ratings: 4
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 261.00 Median: 336.25 Highest: 432.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Amgen Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
07/29/26 Barclays Capital
Maintained Hold $360
07/13/26 UBS
Maintained Buy $420
07/13/26 Guggenheim
Maintained Hold $343
07/08/26 Morgan Stanley
Maintained Hold $333
07/06/26 Cantor Fitzgerald
Maintained Hold $350
06/16/26 Mizuho
Maintained Hold $303
06/10/26 Morgan Stanley
Maintained Hold $340
05/14/26 Piper Sandler
Maintained Buy $427
05/04/26 Guggenheim
Maintained Hold $340
04/21/26 Capital Depesche
Maintained Hold $366
04/13/26 UBS
Maintained Buy $400
04/10/26 Morgan Stanley
Maintained Hold $326
04/09/26 Guggenheim
Maintained Hold $351
04/08/26 Cantor Fitzgerald
Maintained Hold $350
03/10/26 Jefferies & Company Inc.
Maintained Hold $350
02/20/26 Barclays Capital
Maintained Hold $350
02/19/26 Wells Fargo & Co
Maintained Hold $375
02/18/26 Piper Sandler
Maintained Buy $432
02/06/26 Argus Research Company
Maintained Buy $400
02/06/26 Guggenheim
Maintained Hold $347
02/04/26 Citigroup Corp.
Maintained Hold $345
02/04/26 Morgan Stanley
Maintained Hold $309
02/04/26 Cantor Fitzgerald
Maintained Hold $350
01/26/26 UBS
Maintained Buy $390
01/20/26 Bernstein
Downgraded to Hold $335
01/07/26 UBS
Maintained Buy $380
12/12/25 Morgan Stanley
Maintained Hold $304
12/10/25 Wells Fargo & Co
Maintained Hold $325
12/03/25 BMO Capital Markets
Maintained Buy $372
11/14/25 Piper Sandler
Maintained Buy $381
11/06/25 Cantor Fitzgerald
Maintained Hold $315
11/05/25 Morgan Stanley
Maintained Hold $329
11/05/25 Wells Fargo & Co
Maintained Buy $300
09/26/25 Bank of America Merrill Lynch
Maintained Sell $272
09/03/25 Raymond James Financial, Inc.
Maintained Hold
08/25/25 Piper Sandler
Maintained Buy $342
08/06/25 Citigroup Corp.
Maintained Hold $310
08/06/25 Morgan Stanley
Maintained Hold $333
08/06/25 UBS
Maintained Hold $317
07/23/25 Bank of America Merrill Lynch
Maintained Sell $261
07/22/25 Citigroup Corp.
Maintained Hold $305
07/21/25 UBS
Maintained Hold $326
06/27/25 Piper Sandler
Maintained Buy $328
06/24/25 Cantor Fitzgerald
Maintained Hold $305
05/20/25 Guggenheim
Maintained Hold $288
05/16/25 Piper Sandler
Maintained Buy $328
05/07/25 Mizuho
Maintained Hold $280
05/02/25 UBS
Maintained Hold $315
05/02/25 RBC Capital Markets
Maintained Buy $320
04/14/25 UBS
Maintained Hold $319

Amgen Estimates* in USD

  2026 2027 2028 2029 2030
Revenue 37,740 38,736 39,782 41,124 42,689
Dividend 10.21 10.84 11.07 11.74 12.48
Dividend Yield (in %) 2.65 % 2.81 % 2.87 % 3.05 % 3.24 %
EPS 22.36 23.42 24.42 25.85 27.48
P/E Ratio 17.23 16.45 15.77 14.90 14.02
EBIT 16,489 16,977 17,451 18,342 19,300
EBITDA - - - 20,446 21,525
Net Profit 12,106 12,611 13,125 13,897 14,761
Net Profit Adjusted 12,106 12,611 13,145 13,939 14,813
Pre-Tax Profit 14,298 14,989 15,655 16,646 17,758
Pre-Tax Profit Reported 9,289 10,561 11,016 12,080 13,350
EPS (Non-GAAP) ex. SOE - - - - -
EPS (GAAP) 15.89 16.98 17.04 19.05 20.17
Gross Income 29,953 30,658 31,929 33,947 35,377
Cash Flow from Investing -2,060 -2,369 -2,913 -3,633 -3,967
Cash Flow from Operations 12,616 14,458 15,386 17,046 18,190
Cash Flow from Financing -5,777 -7,686 -8,490 -6,944 -7,532
Cash Flow per Share 28.19 27.02 28.26 - -
Free Cash Flow 9,749 9,955 10,728 9,171 14,548
Free Cash Flow per Share - - - - -
Book Value per Share 19.82 23.63 28.64 18.43 21.78
Net Debt 41,325 36,403 30,725 23,158 -
Research & Development Exp. 7,355 7,468 7,663 7,829 8,032
Capital Expenditure 2,103 2,178 2,096 2,805 3,435
Selling, General & Admin. Exp. 6,993 7,163 7,402 7,632 7,764
Shareholder’s Equity 12,135 17,419 23,574 32,349 40,486
Total Assets 95,786 99,069 104,269 110,220 121,909
  Previous Quarter
ending 06/30/26 		Current Quarter
ending 09/30/26 		Next Quarter
ending 12/31/26 		Current Year
ending 12/31/26 		Next Year
ending 12/31/27
Earnings Estimates
No. of Analysts 28 26 26 31 31
Average Estimate 5.617 USD 5.776 USD 5.772 USD 22.356 USD 23.416 USD
Year Ago 2.662 USD 5.978 USD 2.473 USD 14.333 USD -
Publish Date 8/4/2026 11/3/2026 2/9/2027 - -
Revenue Estimates
No. of Analysts 25 23 23 29 29
Average Estimate 9,426 USD 9,695 USD 9,983 USD 37,740 USD 38,736 USD
Year Ago 9,167 USD 9,585 USD 9,896 USD 36,741 USD -
Publish Date 8/4/2026 11/3/2026 2/9/2027 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2025 2024 2023 2022 2021 2020 2019
Sales 36,741.00 33,232.00 28,010.00 26,092.00 25,987.00 25,246.00 23,261.00
Change of sales in % 10.56 18.64 7.35 0.40 2.94 8.53 -2.13
Gross profit on sales 26,012.00 21,333.00 20,301.00 19,686.00 19,533.00 19,087.00 18,905.00
Gross profit on sales change in % 21.93 5.08 3.12 0.78 2.34 0.96 -3.87
Operating income 10,676.00 8,313.00 9,177.00 9,335.00 9,152.00 8,961.00 9,573.00
Operating income change in % 28.43 -9.41 -1.69 2.00 2.13 -6.39 -7.29
Income before tax 8,976.00 4,609.00 7,855.00 7,346.00 6,701.00 8,133.00 9,138.00
Income before tax change in % 94.75 -41.32 6.93 9.63 -17.61 -11.00 -4.26
Income after tax 7,711.00 4,090.00 6,717.00 6,552.00 5,893.00 7,264.00 7,842.00
Income after tax change in % 88.53 -39.11 2.52 11.18 -18.87 -7.37 -6.58

Balance Sheet in Mio. USD

2025 2024 2023 2022 2021 2020 2019
Total liabilities 81,928.00 85,962.00 90,922.00 61,460.00 54,465.00 53,539.00 50,034.00
Long-term liabilities per share 104.75 117.09 135.47 85.72 75.73 72.43 62.90
Equity 8,658.00 5,877.00 6,232.00 3,661.00 6,700.00 9,409.00 9,673.00
Equity change in % 47.32 -5.70 70.23 -45.36 -28.79 -2.73 -22.62
Balance sheet total 90,586.00 91,839.00 97,154.00 65,121.00 61,165.00 62,948.00 59,707.00
Balance sheet total change in % -1.36 -5.47 49.19 6.47 -2.83 5.43 -10.10

Key Data in USD

2025 2024 2023 2022 2021 2020 2019
Sales per share 67.79 61.43 52.06 48.23 45.35 42.79 38.20
P/E ratio (year end quote, basic EPS) 23.01 34.48 23.07 21.69 21.87 18.67 18.72
P/E ratio (year end quote, diluted EPS) 23.01 34.48 23.07 21.69 21.87 18.67 18.72
Dividend yield in % 2.91 3.45 2.96 2.95 3.13 2.78 2.41
Equity ratio in % 9.56 6.40 6.41 5.62 10.95 14.95 16.20
Debt ratio in % 90.44 93.60 93.59 94.38 89.05 85.05 83.80

Amgen Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Klotman Mary E. 05/18/2026 665.00 2,211.00 n/a Buy No
MILES AMY E 05/18/2026 665.00 5,640.00 n/a Buy No
HOLLEY CHARLES M 05/18/2026 665.00 12,799.03 n/a Buy No
ISHRAK OMAR 05/18/2026 665.00 7,358.74 n/a Buy No
Jacks Tyler 05/18/2026 665.00 18,284.00 n/a Buy No
Kullman Ellen Jamison 05/18/2026 665.00 14,535.98 n/a Buy No
Garland Greg C. 05/18/2026 665.00 13,848.00 n/a Buy No
ECKERT ROBERT 05/18/2026 665.00 26,251.00 n/a Buy No
Bradner James E. 05/06/2026 446.00 30,016.00 331.11 Sell No
Bradway Robert A 05/06/2026 2,079.00 505,160.00 331.11 Sell No
Grygiel Nancy A. 05/06/2026 88.00 7,330.00 331.11 Sell No
REESE DAVID M 05/06/2026 556.00 42,256.00 331.11 Sell No
Graham Jonathan P 05/06/2026 499.00 39,712.00 331.11 Sell No
Santos Esteban 05/06/2026 522.00 82,847.00 331.11 Sell No
Miller Derek 05/06/2026 151.00 12,444.00 331.11 Sell No
Busch Matthew C. 05/06/2026 41.00 4,344.00 331.11 Sell No
Griffith Peter H. 05/06/2026 556.00 50,150.00 331.11 Sell No
Khosla Rachna 05/06/2026 93.00 8,394.00 331.11 Sell No
Gordon Murdo 05/06/2026 615.00 51,222.00 331.11 Sell No
Graham Jonathan P 05/05/2026 408.00 40,211.00 329.59 Sell No
Miller Derek 05/05/2026 123.00 12,595.00 329.59 Sell No
Busch Matthew C. 05/05/2026 50.00 4,385.00 329.59 Sell No
REESE DAVID M 05/05/2026 454.00 42,812.00 329.59 Sell No
Santos Esteban 05/05/2026 427.00 83,369.00 329.59 Sell No
Khosla Rachna 05/05/2026 79.00 8,487.00 329.59 Sell No

Amgen Dividend Calendar

Date Name Dividend *yield Currency
2025 Amgen Inc. 9.52 2.91 USD
2024 Amgen Inc. 9.00 3.45 USD
2023 Amgen Inc. 8.52 2.96 USD
2022 Amgen Inc. 7.76 2.95 USD
2021 Amgen Inc. 7.04 3.13 USD
2020 Amgen Inc. 6.40 2.78 USD
2019 Amgen Inc. 5.80 2.41 USD
2018 Amgen Inc. 5.28 2.71 USD
2017 Amgen Inc. 4.60 2.65 USD
2016 Amgen Inc. 4.00 2.74 USD
2015 Amgen Inc. 3.16 1.95 USD
2014 Amgen Inc. 2.44 1.53 USD
2013 Amgen Inc. 1.88 1.65 USD
2012 Amgen Inc. 1.44 1.67 USD
2011 Amgen Inc. 0.56 0.87 USD
2010 Amgen Inc. 0.00 0.00 USD
2009 Amgen Inc. 0.00 0.00 USD
2008 Amgen Inc. 0.00 0.00 USD
2007 Amgen Inc. 0.00 0.00 USD
2006 Amgen Inc. 0.00 0.00 USD
2005 Amgen Inc. 0.00 0.00 USD
2004 Amgen Inc. 0.00 0.00 USD
2003 Amgen Inc. 0.00 0.00 USD
2002 Amgen Inc. 0.00 0.00 USD
2001 Amgen Inc. 0.00 0.00 USD
2000 Amgen Inc. 0.00 0.00 USD
1999 Amgen Inc. 0.00 0.00 USD
*Yield of the Respective Date

Amgen Calendar

Event Estimate Info Date
Earnings Report 5.617 USD Q2 2026 Earnings Release 08/04/2026
Earnings Report 5.776 USD Q3 2026 Earnings Release 11/03/2026
Earnings Report 5.772 USD Q4 2026 Earnings Release 02/09/2027
Earnings Report 5.422 USD Q1 2027 Earnings Release 04/28/2027
Earnings Report 5.967 USD Q2 2027 Earnings Release 08/05/2027

Amgen Past Events

Event Actual EPS Info Date
Annual General Meeting 14.230 USD Annual General Meeting 05/19/2026
Earnings Report 3.340 USD Q1 2026 Earnings Release 04/30/2026
Earnings Report 2.450 USD Q4 2025 Earnings Release 02/03/2026
Earnings Report 5.930 USD Q3 2025 Earnings Release 11/04/2025
Earnings Report 2.650 USD Q2 2025 Earnings Release 08/05/2025
Annual General Meeting 7.560 USD Annual General Meeting 05/23/2025
Earnings Report 3.200 USD Q1 2025 Earnings Release 05/01/2025
Earnings Report 1.160 USD Q4 2024 Earnings Release 02/04/2025
Earnings Report 5.220 USD Q3 2024 Earnings Release 10/30/2024
Earnings Report 1.380 USD Q2 2024 Earnings Release 08/06/2024
Annual General Meeting 12.490 USD Annual General Meeting 05/31/2024
Earnings Report -0.210 USD Q1 2024 Earnings Release 05/02/2024
Earnings Report 1.420 USD Q4 2023 Earnings Release 02/06/2024
Earnings Report 3.220 USD Q3 2023 Earnings Release 10/31/2023
Earnings Report 2.570 USD Q2 2023 Earnings Release 08/03/2023
Annual General Meeting 12.110 USD Annual General Meeting 05/19/2023
Earnings Report 5.280 USD Q1 2023 Earnings Release 04/27/2023
Earnings Report 3.000 USD Q4 2022 Earnings Release 01/31/2023
Earnings Report 3.980 USD Q3 2022 Earnings Release 11/03/2022
Earnings Report 2.450 USD Q2 2022 Earnings Release 08/04/2022
Annual General Meeting 10.280 USD Annual General Meeting 05/17/2022
Earnings Report 2.680 USD Q1 2022 Earnings Release 04/27/2022
Earnings Report 3.360 USD Q4 2021 Earnings Release 02/07/2022

Amgen Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
6
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Amgen Management

Name Job
Robert A. Bradway Chairman, President & Chief Executive Officer
Matthew C. Busch Chief Accounting Officer & Vice President-Finance
Linda H. Louie Chief Accounting Officer & Vice President-Finance
Nancy A. Grygiel Chief Compliance Officer
Peter H. Griffith Chief Financial Officer
Scott Skellenger Chief Information Officer & Senior Vice President
Paul Burton Chief Medical Officer & Senior Vice President
Jackie Elbonne Chief Quality Officer & Senior Vice President
Howard Y. Chang Chief Scientific Officer & SVP-Global Research
Sean Bruich Chief Technology Officer & Senior Vice President
Murdo J. Gordon Executive VP-Amgen Global Markets & Policy
Susan Sweeney Executive VP-Obesity & Related Conditions
James E. Bradner Executive VP-Research & Development
Thomas Johannes W. Dittrich Executive Vice President
Esteban Santos Executive Vice President-Operations
Amy E. Miles Independent Director
Ellen Jamison Kullman Independent Director
Gregory C. Garland Independent Director
Wanda M. Austin Independent Director
Brian J. Druker Independent Director
Mary Earley Klotman Independent Director
Tyler E. Jacks Independent Director
Omar Syed Ishrak Independent Director
Charles M. Holley Independent Director
Michael V. Drake Independent Director
Robert A. Eckert Lead Independent Director
Jonathan P. Graham Secretary, Executive VP & General Counsel
Greg Portner Senior VP-Global Government Affairs & Policy
Mark J. Taisey Senior VP-Global Regulatory Affairs & Strategy
Jean-Charles Soria Senior VP-Research & Development
Rachna Khosla Senior Vice President-Business Development
Sam Guhan Senior Vice President-Global Engineering
Kave Niksefat Senior Vice President-Global Marketing & Access
Derek Miller Senior Vice President-Human Resources
Justin Gary Claeys VP, Head-Financial Planning & Analysis
Xue Jun Cai Vice President
Casey Capparelli Vice President-Investor Relations